Stephen A. Boorjian

33.4k total citations · 6 hit papers
569 papers, 20.8k citations indexed

About

Stephen A. Boorjian is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Molecular Biology. According to data from OpenAlex, Stephen A. Boorjian has authored 569 papers receiving a total of 20.8k indexed citations (citations by other indexed papers that have themselves been cited), including 333 papers in Pulmonary and Respiratory Medicine, 299 papers in Surgery and 114 papers in Molecular Biology. Recurrent topics in Stephen A. Boorjian's work include Bladder and Urothelial Cancer Treatments (256 papers), Renal cell carcinoma treatment (193 papers) and Urinary and Genital Oncology Studies (135 papers). Stephen A. Boorjian is often cited by papers focused on Bladder and Urothelial Cancer Treatments (256 papers), Renal cell carcinoma treatment (193 papers) and Urinary and Genital Oncology Studies (135 papers). Stephen A. Boorjian collaborates with scholars based in United States, Canada and Germany. Stephen A. Boorjian's co-authors include R. Houston Thompson, Bradley C. Leibovich, Christine M. Lohse, John C. Cheville, Michael L. Blute, Igor Frank, R. Jeffrey Karnes, Matthew K. Tollefson, Prabin Thapa and Brian A. Costello and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Internal Medicine.

In The Last Decade

Stephen A. Boorjian

540 papers receiving 20.6k citations

Hit Papers

Epidemiology of Renal Cell Carcinoma 2008 2026 2014 2020 2018 2016 2008 2015 2022 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Epidemiology of Renal Cell Carcinoma
    2018 1.0k citations Umberto Capitanio, Stephen A. Boorjian et al. European Urology profile →
  2. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline
    2016 937 citations Stephen A. Boorjian, Roger Chou et al. The Journal of Urology profile →
  3. Radical Nephrectomy for pT1a Renal Masses May be Associated With Decreased Overall Survival Compared With Partial Nephrectomy
    2008 517 citations R. Houston Thompson, Stephen A. Boorjian et al. The Journal of Urology profile →
  4. Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
    2015 467 citations Siamak Daneshmand, Yair Lotan et al. European Urology profile →
  5. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management
    2022 226 citations Roger Chou, Scott E. Eggener et al. The Journal of Urology profile →
  6. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up
    2022 124 citations Roger Chou, Scott E. Eggener et al. The Journal of Urology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stephen A. Boorjian United States 72 12.2k 9.3k 6.4k 3.9k 2.5k 569 20.8k
Hendrik Van Poppel Belgium 82 19.0k 1.6× 6.5k 0.7× 6.7k 1.0× 3.3k 0.8× 2.3k 0.9× 567 24.9k
Igor Frank United States 57 8.4k 0.7× 5.7k 0.6× 4.7k 0.7× 2.8k 0.7× 1.4k 0.6× 243 13.2k
R. Houston Thompson United States 69 12.6k 1.0× 5.5k 0.6× 7.6k 1.2× 4.8k 1.2× 799 0.3× 424 18.5k
Maxine Sun United States 64 9.8k 0.8× 6.4k 0.7× 3.1k 0.5× 3.3k 0.8× 1.9k 0.8× 435 15.8k
Michael A.S. Jewett Canada 69 8.9k 0.7× 6.1k 0.7× 6.5k 1.0× 2.0k 0.5× 1.0k 0.4× 418 15.7k
Adam S. Kibel United States 60 8.7k 0.7× 4.6k 0.5× 3.3k 0.5× 3.4k 0.9× 1.7k 0.7× 605 15.9k
Éva Compérat France 59 6.0k 0.5× 15.0k 1.6× 4.2k 0.7× 3.9k 1.0× 5.0k 2.0× 367 20.8k
Bradley C. Leibovich United States 81 17.9k 1.5× 7.1k 0.8× 11.1k 1.7× 6.0k 1.5× 747 0.3× 456 24.4k
James W.F. Catto United Kingdom 64 4.4k 0.4× 8.5k 0.9× 4.7k 0.7× 3.1k 0.8× 2.4k 1.0× 295 15.8k
E. David Crawford United States 64 11.4k 0.9× 4.4k 0.5× 4.0k 0.6× 4.0k 1.0× 1.4k 0.6× 284 17.5k

Countries citing papers authored by Stephen A. Boorjian

Since Specialization
Citations

This map shows the geographic impact of Stephen A. Boorjian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen A. Boorjian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen A. Boorjian more than expected).

Fields of papers citing papers by Stephen A. Boorjian

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen A. Boorjian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen A. Boorjian. The network helps show where Stephen A. Boorjian may publish in the future.

Co-authorship network of co-authors of Stephen A. Boorjian

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen A. Boorjian. A scholar is included among the top collaborators of Stephen A. Boorjian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen A. Boorjian. Stephen A. Boorjian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nguyen, Mimi Thi, et al.. (2025). Real-world outcomes of nadofaragene firadenovec in BCG-unresponsive non-muscle invasive bladder cancer.. Journal of Clinical Oncology. 43(5_suppl). 716–716. 2 indexed citations
2.
Daneshmand, Siamak, Stephen A. Boorjian, Joshua J. Meeks, et al.. (2025). ABLE-22: Safety and efficacy evaluation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy—A randomized, open-label, phase 2 study.. Journal of Clinical Oncology. 43(5_suppl).
3.
Morgan, Todd M., Stephen A. Boorjian, Mark K. Buyyounouski, et al.. (2024). Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. The Journal of Urology. 211(4). 526–532. 13 indexed citations
4.
Joyce, Daniel, Kasey R. Boehmer, Celia Kamath, et al.. (2024). Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Mixed Methods Approach to Identify Effective Interventions. Urology Practice. 11(4). 640–652. 1 indexed citations
5.
Jong, Joep J. de, Tarek A. Bismar, Stephen A. Boorjian, et al.. (2024). Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers. Urologic Oncology Seminars and Original Investigations. 42(6). 177.e5–177.e14. 1 indexed citations
6.
Ahmed, Mohamed E., Jack R. Andrews, Ahmed Mahmoud, et al.. (2023). Survival patterns based on site-specific visceral metastasis in patients with metastatic prostate cancer: Are outcomes of visceral metastases the same?. Journal of Clinical Oncology. 41(6_suppl). 269–269. 1 indexed citations
7.
Toussi, Amir, Matthew Ziegelmann, Igor Frank, et al.. (2023). Efficacy of RestoreX after prostatectomy: open‐label phase of a randomized controlled trial. British Journal of Urology. 132(2). 217–226. 4 indexed citations
8.
Joyce, Daniel, Kevin Wymer, Vidit Sharma, et al.. (2022). Comparative cost‐effectiveness of neoadjuvant chemotherapy regimens for muscle‐invasive bladder cancer: Results according to VESPER data. Cancer. 128(24). 4194–4202. 9 indexed citations
9.
Daneshmand, Siamak, Clint Cary, Timothy A. Masterson, et al.. (2021). SEMS trial: Result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma.. Journal of Clinical Oncology. 39(6_suppl). 375–375. 21 indexed citations
10.
Clements, Matthew, Emily Vertosick, Amanda M. De Hoedt, et al.. (2021). Defining the Impact of Family History on Detection of High-grade Prostate Cancer in a Large Multi-institutional Cohort. European Urology. 82(2). 163–169. 24 indexed citations
11.
Juvet, Tristan, Stephen A. Boorjian, Igor Frank, et al.. (2020). Intraoperative application of platelet-rich plasma to the neurovascular bundles during radical prostatectomy: A prospective clinical trial. European Urology Open Science. 19. e769–e769. 1 indexed citations
12.
Moschini, Marco, Shahrokh F. Shariat, Peter C. Black, et al.. (2019). Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. European Urology. 77(1). 1–2. 4 indexed citations
13.
Rieken, Malte, Stephen A. Boorjian, Luis A. Kluth, et al.. (2018). Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma. World Journal of Urology. 37(8). 1631–1637. 4 indexed citations
14.
Ankerst, Donna P., Amanda M. De Hoedt, Javier Hernández, et al.. (2018). A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. European Urology. 74(2). 197–203. 99 indexed citations
15.
Boeri, Luca, Matteo Soligo, Igor Frank, et al.. (2018). Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes. European Urology Oncology. 2(4). 390–396. 52 indexed citations
16.
Linder, Brian J., Edward Bass, Hugh Mostafid, & Stephen A. Boorjian. (2017). Guideline of guidelines: asymptomatic microscopic haematuria. British Journal of Urology. 121(2). 176–183. 54 indexed citations
17.
Wallis, Christopher J.D., Zachary Klaassen, Bimal Bhindi, et al.. (2017). Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. European Urology. 73(6). 834–844. 79 indexed citations
18.
Stewart‐Merrill, Suzanne B., Fares Alahdab, Khalid Benkhadra, et al.. (2016). Oncologic surveillance in bladder cancer following radical cystectomy: A systematic review and meta-analysis. Urologic Oncology Seminars and Original Investigations. 34(5). 236.e13–236.e21. 8 indexed citations
19.
Fossati, Nicola, R. Jeffrey Karnes, C. Cozzarini, et al.. (2015). Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. European Urology. 69(4). 728–733. 73 indexed citations
20.
Boorjian, Stephen A., Yuri Sheinin, Paul L. Crispen, et al.. (2008). T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival. Clinical Cancer Research. 14(15). 4800–4808. 217 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hendrik Van Poppel Breakdown of academic impact, for papers by Igor Frank Breakdown of academic impact, for papers by R. Houston Thompson Breakdown of academic impact, for papers by Maxine Sun Breakdown of academic impact, for papers by Michael A.S. Jewett Breakdown of academic impact, for papers by Adam S. Kibel Breakdown of academic impact, for papers by Éva Compérat Breakdown of academic impact, for papers by Bradley C. Leibovich Breakdown of academic impact, for papers by James W.F. Catto Breakdown of academic impact, for papers by E. David Crawford
Rankless by CCL
2026